Santhera to Report Half-Year 2016 Financial Results on Tuesday, September 6, 2016

Santhera Pharmaceuticals Holding AG / Santhera to Report Half-Year 2016 Financial Results on Tuesday, September 6, 2016 . Verarbeitet und übermittelt durch Nasdaq Corporate Solutions. Für den Inhalt der Mitteilung ist der Emittent verantwortlich. Source: Globenewswire

Liestal, Switzerland, August 29, 2016 - Santhera Pharmaceuticals (SIX: SANN), a Swiss specialty pharmaceutical company, will announce the financial results for the first half-year 2016 on Tuesday, September 6, 2016, at 7:00 am CET. An Investor Conference Call with Thomas Meier, PhD, CEO of Santhera Pharmaceuticals, will be held on the same day at 5:00 pm CET.

Participants can call the following numbers 10-15 minutes before Conference's schedule (no code needed):
+41 (0)58 310 50 00 (Europe)
+44 (0)203 059 58 62 (UK)
+1 (1)631 570 5613 (USA)

About Santhera
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative pharmaceutical products for the treatment of orphan mitochondrial and neuromuscular diseases. Santhera's lead product Raxone® is authorized in the European Union, Norway, Iceland and Liechtenstein for the treatment of Leber's hereditary optic neuropathy (LHON). For Duchenne muscular dystrophy (DMD), the second indication for Raxone^®, Santhera has filed a Marketing Authorization Application (MAA) in the European Union. Santhera develops Raxone^® in a third indication, primary progressive multiple sclerosis (PPMS), and omigapil for congenital muscular dystrophy (CMD), all areas of high unmet medical need. For further information, please visit the Company's website www.santhera.com.

Raxone^® is a trademark of Santhera Pharmaceuticals.

For further information, contact:
Thomas Meier, PhD, Chief Executive Officer          Christoph Rentsch, Chief Financial Officer
Phone +41 61 906 89 64                                        Phone +41 61 906 89 65
thomas.meier@santhera.com                                christoph.rentsch@santhera.com

Daniel Piller, Head Communications
Phone +41 61 906 89 26
daniel.piller@santhera.com

US investor contact                                             US Public Relations contact
Hans Vitzthum, LifeSci Advisors, LLC                    Deanne Eagle, Planet Communications
Phone +1 212 915 2568                                         Phone +1 917 837 5866
hans@lifesciadvisors.com                                    deanne@planetcommunications.nyc

Disclaimer / Forward-looking statements
This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.

# # #

--- Ende der Mitteilung ---

Santhera Pharmaceuticals Holding AG
Hammerstrasse 49 Liestal Schweiz

ISIN: CH0027148649;